LD-2 disclosure · 1st Quarter - Report
ASSOCIATION FOR ACCESSIBLE MEDICINES
Client
- Location
- District of Columbia · United States of America
Registrant
- Description
- Association representing the interests of the generic pharmaceutical industry.
- Location
- Washington, District of Columbia, United States of America
Lobbying activities
4 issuesMedicare/Medicaid
Medicare Part D Reform. Medicaid Rebate Penalty. Medicare/Medicaid Inflation Penalties. Medicare Conditions of Participation. CMS RFC on Domestic Manufacturing. PBM Bid Transparency.
LobbyistsKARIN HESSLER · PETER KELBEL · ILHAAM JAFFER · JOHN MURPHY · MARK RATNER · ALEX KEETON
TargetedSENATE · HOUSE OF REPRESENTATIVES · Centers For Medicare and Medicaid Services (CMS)
Pharmacy
Prescription Drug Costs. H.R.1843: To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications. S.1302: Increasing Transparency in Generic Drug Applications Act. Generic Drug Reporting Requirement Language in Public Law No. 119-60: National Defense Authorization Act for Fiscal Year 2026. Public Law No. 119-60: National Defense Authorization Act for Fiscal Year 2026. H.R.1396/S.1891: Producing Incentives for Long-term Production of Lifesaving Supply of Medicine (PILLS) Act. Drug Shortages. H.R.5526/S.1954: Biosimilar Red Tape Elimination Act (BRTEA). American Relief Act, 2025 (PL. No: 118-158) as it relates to Patent Thickets and Q1/Q2. H.R.3955/S.2062: RAPID Reserve Act. H.R.4132/S.2027: Prescription Information Modernization Act of 2025. S.1414/H.R.__: Expedited Access to Biosimilars Act. S.3469: BIOSECURE Act of 2025. Quotas on Controlled Substances. Hassan Purple Book Proposal. S.3788: Consumer Labeling for Enhanced API Reporting and Legitimate Accountability for Base Entity Listings (CLEAR LABELS) Act. PBM Bid Transparency. H.R.7148 - Consolidated Appropriations Act, 2026 as it relates to PBM reforms and Q1/Q2.
LobbyistsKARIN HESSLER · PETER KELBEL · ILHAAM JAFFER · JOHN MURPHY · MARK RATNER · ALEX KEETON
